Provided By GlobeNewswire
Last update: Jun 5, 2024
Collaboration will leverage Alphamab’s antibody drug conjugate (“ADC”) research and discovery platform and ArriVent’s global development and commercialization expertise
NASDAQ:AVBP (7/25/2025, 9:45:34 AM)
21.36
-0.09 (-0.42%)
Find more stocks in the Stock Screener